Evolent Health (NYSE:EVH) versus Fluidigm Corporation (FLDM) Critical Comparison

Fluidigm Corporation (NASDAQ: FLDM) and Evolent Health (NYSE:EVH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Analyst Ratings

This is a summary of recent ratings and price targets for Fluidigm Corporation and Evolent Health, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fluidigm Corporation 0 0 1 0 3.00
Evolent Health 0 0 11 1 3.08

Fluidigm Corporation presently has a consensus target price of $9.00, suggesting a potential upside of 147.25%. Evolent Health has a consensus target price of $30.33, suggesting a potential upside of 77.91%. Given Fluidigm Corporation’s higher possible upside, analysts clearly believe Fluidigm Corporation is more favorable than Evolent Health.

Institutional and Insider Ownership

91.4% of Fluidigm Corporation shares are owned by institutional investors. Comparatively, 68.1% of Evolent Health shares are owned by institutional investors. 4.7% of Fluidigm Corporation shares are owned by company insiders. Comparatively, 8.8% of Evolent Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Fluidigm Corporation has a beta of 3.45, meaning that its stock price is 245% more volatile than the S&P 500. Comparatively, Evolent Health has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.

Earnings & Valuation

This table compares Fluidigm Corporation and Evolent Health’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Fluidigm Corporation $96.72 million 1.11 -$62.62 million ($2.46) -1.48
Evolent Health $361.53 million 3.10 -$51.15 million ($1.21) -14.09

Evolent Health has higher revenue and earnings than Fluidigm Corporation. Evolent Health is trading at a lower price-to-earnings ratio than Fluidigm Corporation, indicating that it is currently the more affordable of the two stocks.


This table compares Fluidigm Corporation and Evolent Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fluidigm Corporation -74.05% -121.04% -18.55%
Evolent Health -17.57% -6.44% -5.13%


Evolent Health beats Fluidigm Corporation on 11 of the 14 factors compared between the two stocks.

About Fluidigm Corporation

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.

About Evolent Health

Evolent Health, Inc. is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models. The Company’s services include providing its customers, with a population management platform, integrated data and analytics capabilities, pharmacy benefit management (PBM) services and comprehensive health plan administration services. Its value-based operations are empowered and supported by Identifi. Identifi is the Company’s technology platform that aggregates and analyzes data, manages care workflows and engages patients.

Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply